Literature DB >> 20304469

Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers.

Noritaka Higashi1, Haruhisa Mita, Emiko Ono, Yuma Fukutomi, Hiromichi Yamaguchi, Keiichi Kajiwara, Hidenori Tanimoto, Kiyoshi Sekiya, Kazuo Akiyama, Masami Taniguchi.   

Abstract

BACKGROUND: It has recently demonstrated that a free radical-mediated pathway generates prostaglandins (PGs) and the corresponding prostaglandin enantiomers (ent-PGs). Aspirin-intolerant asthma and anaphylaxis accompany PGD(2) overproduction, possibly associated with mast cell activation via the COX pathway. However, free radical-mediated PG generation in the pathophysiology of these diseases, which can be demonstrated by measuring urinary ent-PGF(2)alpha, has not been reported.
OBJECTIVES: To evaluate the characteristic profile of eicosanoid generation via the COX and/or free radical-mediated pathway underlying aspirin-intolerant asthma and anaphylaxis.
METHODS: A comparative group analysis consisted of asthma (n = 17) and anaphylaxis (n = 8, none with aspirin-induced anaphylaxis) cases. Urinary eicosanoid concentrations were quantified as follows: 2,3-dinor-9alpha,11beta-PGF(2) by gas chromatography-mass spectrometry; leukotriene E(4), 9alpha,11beta-PGF(2), and PGs by enzyme immunoassay.
RESULTS: 2,3-Dinor-9alpha,11beta-PGF(2) is a more predominant PGD(2) metabolite in urine than 9alpha,11beta-PGF(2). At baseline, the aspirin-intolerant asthma group (n = 10) had significantly higher leukotriene E(4) and lower PGE(2) concentrations in urine than the aspirin-tolerant asthma group. During the reaction, the urinary concentrations of leukotriene E(4) and PGD(2) metabolites correlatively increased, but with markedly different patterns of the mediator release, in the aspirin-intolerant asthma group and the anaphylaxis group, respectively. The urinary PGD(2) metabolites and primary PGs were significantly decreased in the aspirin-tolerant asthma group. Urinary ent-PGF(2)alpha concentrations were significantly increased in the anaphylaxis group but not the aspirin-intolerant asthma group.
CONCLUSIONS: When assessed by urinary 2,3-dinor-9alpha,11beta-PGF(2), PGD(2) overproduction during aspirin-intolerant bronchoconstriction was clearly identified, regardless of COX inhibition. It is evident that free radical-mediated PG generation is involved in the pathophysiology of anaphylaxis. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304469     DOI: 10.1016/j.jaci.2009.12.977

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

Review 1.  The pathophysiology of anaphylaxis.

Authors:  Laurent L Reber; Joseph D Hernandez; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2017-08       Impact factor: 10.793

2.  Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease.

Authors:  Xin Feng; Madison K Ramsden; Julie Negri; Mary Grace Baker; Spencer C Payne; Larry Borish; John W Steinke
Journal:  J Allergy Clin Immunol       Date:  2016-06-14       Impact factor: 10.793

3.  Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease.

Authors:  Elina Jerschow; Zhen Ren; Golda Hudes; Marek Sanak; Esperanza Morales; Victor Schuster; Simon D Spivack; David Rosenstreich
Journal:  Ann Allergy Asthma Immunol       Date:  2016-01-25       Impact factor: 6.347

4.  Exhaled Eicosanoids following Bronchial Aspirin Challenge in Asthma Patients with and without Aspirin Hypersensitivity: The Pilot Study.

Authors:  L Mastalerz; M Sanak; J Kumik; A Gawlewicz-Mroczka; N Celejewska-Wójcik; A Cmiel; A Szczeklik
Journal:  J Allergy (Cairo)       Date:  2012-01-12

5.  Biomarkers for predicting response to aspirin therapy in aspirin-exacerbated respiratory disease.

Authors:  Katarzyna E Tyrak; Kinga Pajdzik; Bogdan Jakieła; Izabela Kupryś-Lipińska; Adam Ćmiel; Radosław Kacorzyk; Gabriela Trąd; Piotr Kuna; Marek Sanak; Lucyna Mastalerz
Journal:  Clin Exp Allergy       Date:  2021-05-11       Impact factor: 5.401

6.  Variants of CEP68 gene are associated with acute urticaria/angioedema induced by multiple non-steroidal anti-inflammatory drugs.

Authors:  José Antonio Cornejo-García; Carlos Flores; María C Plaza-Serón; Marialbert Acosta-Herrera; Natalia Blanca-López; Inmaculada Doña; María J Torres; Cristobalina Mayorga; Rosa M Guéant-Rodríguez; Pedro Ayuso; Javier Fernández; José J Laguna; José A G Agúndez; Elena García-Martín; Jean-Louis Guéant; Gabriela Canto; Miguel Blanca
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

7.  UPLC-MS/MS-Based Profiling of Eicosanoids in RAW264.7 Cells Treated with Lipopolysaccharide.

Authors:  Jae Won Lee; Hyuck Jun Mok; Dae-Young Lee; Seung Cheol Park; Myeong Soon Ban; Jehun Choi; Chun Geon Park; Young-Sup Ahn; Kwang Pyo Kim; Hyung Don Kim
Journal:  Int J Mol Sci       Date:  2016-04-06       Impact factor: 5.923

8.  Signal transduction pathways (MAPKs, NF-κB, and C/EBP) regulating COX-2 expression in nasal fibroblasts from asthma patients with aspirin intolerance.

Authors:  Francesc Josep Garcia-Garcia; Joaquim Mullol; Maria Perez-Gonzalez; Laura Pujols; Isam Alobid; Jordi Roca-Ferrer; Cesar Picado
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

9.  9α,11β-PGF2, a Prostaglandin D2 Metabolite, as a Marker of Mast Cell Activation in Bee Venom-Allergic Patients.

Authors:  Marita Nittner-Marszalska; Ewa Cichocka-Jarosz; Marek Sanak; Magdalena Wujczyk; Anna Dor-Wojnarowska; Grzegorz Lis; Jerzy Liebhart
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-03-13       Impact factor: 4.291

Review 10.  Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.

Authors:  Esha Sehanobish; Mohammad Asad; Mali Barbi; Steven A Porcelli; Elina Jerschow
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.